CLSA has initiated coverage on Hyundai Motor India with an ‘Outperform’ rating and a target price of Rs 2,155, citing strong growth prospects amid strategic expansion. The firm notes the company’s promising outlook with new capacity additions planned and competitive advantages, despite recent stock underperformance.
Nifty Pharma, 4 others hit 52-week high since Iran war while Nifty fell 7%. Will the form continue?
Despite a challenging market backdrop fueled by geopolitical tensions and foreign fund outflows, five Indian sectors—Pharma, Energy, Defence, Capital Markets, and Metals—are showing remarkable strength.